DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE CONS, and what generic alternatives to GLAXOSMITHKLINE CONS drugs are available?

GLAXOSMITHKLINE CONS has fifteen approved drugs.

There are eleven US patents protecting GLAXOSMITHKLINE CONS drugs.

Summary for Glaxosmithkline Cons

US Patents:	11
Tradenames:	11
Ingredients:	10
NDAs:	15

Drugs and US Patents for Glaxosmithkline Cons

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Cons	TAVIST-1	clemastine fumarate	TABLET;ORAL	020925-001	Aug 21, 1992		DISCN	Yes	No
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	7,541,350		Y
Glaxosmithkline Cons	LAMISIL AT	terbinafine	GEL;TOPICAL	021958-001	Jul 24, 2006		OTC	Yes	Yes
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	9,320,862		Y
Glaxosmithkline Cons	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009		OTC	Yes	No	8,940,772		Y

Expired US Patents for Glaxosmithkline Cons

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000	5,681,849*PED
Glaxosmithkline Cons	LAMISIL	terbinafine hydrochloride	SOLUTION;TOPICAL	020749-001	Oct 17, 1997	6,121,314*PED
Glaxosmithkline Cons	LAMISIL	terbinafine hydrochloride	SOLUTION;TOPICAL	020749-001	Oct 17, 1997	4,755,534*PED
Glaxosmithkline Cons	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007	4,598,089
Glaxosmithkline Cons	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009	5,110,605

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	60 mg		2010-09-08
	Gum	4 mg		2013-01-22
	Gum	2 mg		2013-01-22

International Patents for Glaxosmithkline Cons Drugs

Country	Document Number	Estimated Expiration
Australia	2005221876
World Intellectual Property Organization (WIPO)	2004024745
Norway	20075376
Brazil	PI0911847
Argentina	032471

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
6	Finland
C0136	Belgium		PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
12/2008	Austria		PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
C0042	Belgium		PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glaxo Grp England
• Glaxo Grp Ltd
• Glaxosmithkline
• Glaxosmithkline Con
• Glaxosmithkline Cons